ReviewJACC. Heart failure2024
Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series.
Review in JACC. Heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 30 citations in OpenAlex.
- Vericiguat in Elderly Patients with Heart Failure and Reduced Ejection Fraction: Clinical Perspectives from Pathophysiology to Implementation.Journal of clinical medicine · 2026Review
- Heart failure in the elderly: epidemiology, mechanisms, and management.European heart journal · 2026Review
- Experiences of Older Adults and Caregivers With Home Telemonitoring for Heart Failure in Canada: Qualitative Study.JMIR aging · 2026Article
- The Impact of Risk Factors and Comorbidities on Heart Failure in the Aging Population.International journal of molecular sciences · 2026Review
- Associations of psychosocial factors with cardiovascular health in aging: insights from the Inlife-Aging Project.GeroScience · 2026Article
- IGFBP7 and Heart Failure: From Senescence Biomarker to Therapeutic Target.Current heart failure reports · 2026Review
- Article
- Global burden of heart failure due to cardiovascular diseases, 1990-2021 and predictions to 2035 based on GBD 2021.ESC heart failure · 2026Article
- Chronic quercetin supplementation modulates cardiac function and signaling pathways in aged male Wistar rat hearts subjected to ischemia-reperfusion.Frontiers in cardiovascular medicine · 2026Article
- Identification and validation of STEAP3 as a ferroptosis-related biomarker in heart failure.Frontiers in cardiovascular medicine · 2026Article
- Clinical Pharmacology of Heart Failure in Frailty.European cardiology · 2026Review
- Safety & efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure.Frontiers in cardiovascular medicine · 2026Article
- The Immunological Consequences of Clonal Hematopoiesis in Heart Failure.Immunological reviews · 2026Review
- AP39 alleviates HHCY-induced myocardial remodeling by regulating FUNDC1-mediated mitochondrial dynamics via S-sulfhydration of NEDD8/CUL4B.Frontiers in pharmacology · 2026Article
- Integrating Senescence and Oxidative Stress in Cardiac Disease.International journal of molecular sciences · 2025Review
- The correlation between serum ECM1 and cardiac fibrosis in heart failure patients.BMC cardiovascular disorders · 2025Article
- Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.Journal of the American Heart Association · 2025Article
- Long-term dietary allyl isothiocyanate, a TRPA1 agonist, ameliorates cardiac fibrosis and diastolic dysfunction in aged mice.GeroScience · 2025Article
- Addressing osteoblast senescence: Molecular pathways and the frontier of anti-ageing treatments.Clinical and translational medicine · 2025Review
- Calcium Signaling Dynamics in Vascular Cells and Their Dysregulation in Vascular Disease.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Age is among the most potent risk factors for developing heart failure and is strongly associated with adverse outcomes. As the global population continues to age and the prevalence of heart failure rises, understanding the role of aging in the development and progression of this chronic disease is essential. Although chronologic age is on a fixed course, biological aging is more variable and potentially modifiable in patients with heart failure. This review describes the current knowledge on mechanisms of biological aging that contribute to the pathogenesis of heart failure. The discussion focuses on 3 hallmarks of aging-impaired proteostasis, mitochondrial dysfunction, and deregulated nutrient sensing-that are currently being targeted in therapeutic development for older adults with heart failure. In assessing existing and emerging therapeutic strategies, the review also enumerates the importance of incorporating geriatric conditions into the management of older adults with heart failure and in ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.